Quick Answer
Yes, fibromyalgia can qualify for the Disability Tax Credit Canada in 2026 when chronic pain and fatigue markedly restrict walking, dressing, or mental functions at least 90% of the time. Documentation should focus on functional impact rather than diagnosis alone, since CRA evaluates day-to-day restrictions, not the condition name.
How Fibromyalgia Can Qualify for DTC
Fibromyalgia claims most commonly qualify under:
- Walking, if widespread pain severely limits walking ability 90%+ of the time
- Dressing, if pain and fatigue prevent independent dressing on most days
- Mental functions, "fibro fog" causing memory, concentration, and cognitive impairment
- Cumulative effect, where multiple moderate restrictions combine to cause an equivalent marked restriction
The Documentation Challenge
Fibromyalgia's biggest obstacle in a DTC claim is the lack of objective test results. Unlike conditions with X-rays, MRIs, or blood markers, fibromyalgia is diagnosed clinically based on symptom presentation. CRA assessors reviewing fibromyalgia claims must rely entirely on what the physician documents.
This means your physician's responses to the T2201 questions must be highly specific and functional, not just "patient has fibromyalgia and is in pain" but "patient cannot walk more than one block without stopping, requires assistance with dressing 7 days a week, and cannot manage basic cognitive tasks for more than 2 hours per day."
Key Documentation for Fibromyalgia DTC
- Detailed physician letter or functional capacity evaluation describing day-to-day limitations
- Occupational therapy assessment (if available), the most powerful objective evidence for functional restriction
- Records of medication history and pain management treatments tried
- Documentation of sleep disturbance severity and its functional impact
- Records showing work inability, disability insurance approvals, or consistent medical appointments
- Physiotherapy or specialist records documenting functional assessments
Cumulative Effect Category
Fibromyalgia often affects multiple activities moderately rather than severely restricting one activity. CRA's cumulative effect provision recognizes this: if two or more activities are each significantly restricted (but not quite "markedly restricted" individually), the combined effect may meet the DTC threshold. This is particularly important for fibromyalgia claims where walking + dressing + mental functions are all moderately impaired.
2026 DTC Amounts
If approved: federal credit $1,481/year. Combined federal + provincial: $2,080-$3,741/year. Retroactive claims for years of severe fibromyalgia can total $14,000-$37,000+.
Real fibromyalgia Filing Scenario
The following example is illustrative. It describes a typical filing flow and does not predict any individual outcome.
A Halifax-area resident with long-standing fibromyalgia met with her family doctor to complete Part B. The doctor documented walking limitation (frequent breaks due to pain and fatigue), dressing taking 3 to 4 times longer than normal, and cognitive impact (commonly called "fibro fog") affecting concentration and processing speed. Part B explicitly addressed section 6, certifying that the combined restrictions take approximately 17 hours per week of extra support and time. The Notice of Determination arrived 14 weeks after submission, approving the DTC retroactive to 2022.
Documentation That Works for Fibromyalgia Part B
What worked in this Part B: explicit cumulative-effect attestation across three restricted activities and concrete weekly-time quantification. Fibromyalgia claims are commonly denied when only pain severity is described; what passes is the cumulative-effect rule applied across walking, dressing, and mental functions. See our cumulative effects rule guide for the technical framework CRA reviewers apply, and our DTC denied appeal guide if a previous application was rejected.
How CRA Applies Section 118.3 to Fibromyalgia
Fibromyalgia is not named in the Income Tax Act or in CRA's published guidance, which is one reason claims for this condition can feel uncertain. The framework CRA reviewers apply is the same general framework used for any condition: section 118.3 of the Income Tax Act requires a severe and prolonged impairment in physical or mental functions, where the individual is markedly restricted in a basic activity of daily living, or where the cumulative effect of significant restrictions is equivalent to a marked restriction.
For fibromyalgia, the practical interpretation laid out in CRA's Income Tax Folio S1-F1-C2, Disability Tax Credit means the medical practitioner must document specific functional restrictions, not just the diagnosis. The folio confirms that pain itself is not a basic activity of daily living; rather, pain that prevents or significantly slows walking, dressing, feeding, or mental functions is what supports a DTC claim. This is the doorway through which fibromyalgia claims succeed.
The Cumulative-Effect Path for Fibromyalgia
Most successful fibromyalgia DTC claims are granted under the cumulative-effect provision of section 118.3, not under a single marked restriction. The reason is structural: fibromyalgia typically causes moderate restrictions across multiple activities rather than a single severe restriction in one activity. The cumulative-effect path recognises this pattern and is the reason completing the cumulative-effect section of Part B carefully matters more here than for many other conditions.
To meet the cumulative-effect threshold, the combined restrictions must take at least 14 hours per week of extra support and time, all or substantially all of the time, and have lasted or be expected to last for at least 12 continuous months. For a fibromyalgia claimant, the cumulative time commonly comes from: extra walking time during flare days, extra dressing and feeding time on high-pain mornings, time lost to cognitive fog affecting routine tasks, and the recovery time required after even modest physical exertion. Our cumulative effects rule guide walks through how to quantify this and what the practitioner should write in section 6 of Part B.
Supporting Documentation Beyond Part B
Fibromyalgia claims benefit from supporting documentation attached to the T2201, because the diagnosis itself has historically been contested in some medical communities. CRA reviewers are more likely to approve when Part B is supported by:
- A rheumatology consultation report confirming the diagnosis using the 2016 American College of Rheumatology criteria or the Canadian Rheumatology Association approach
- A pain clinic assessment if available
- An occupational therapist functional assessment documenting time-on-task for daily activities
- A neurocognitive screening if "fibro fog" is part of the claim, supporting the mental functions component of the cumulative-effect analysis
- A medication and treatment history showing what has been tried (pregabalin, duloxetine, low-dose tricyclics, cognitive behavioural therapy) and what residual restrictions remain
The Tax Court of Canada has decided numerous fibromyalgia DTC appeals under section 118.3, with outcomes that turn on the strength of the documented functional restrictions and the cumulative-effect analysis. Anyone preparing a Notice of Objection after a denied claim can read decisions in their fact pattern at the Tax Court of Canada on CanLII, searching for "fibromyalgia" plus "disability tax credit."
Frequently Asked Questions
No. Fibromyalgia is neither automatically approved nor automatically denied. Approval depends entirely on whether documented functional impairment meets CRA's marked restriction standard. Well-documented severe cases often qualify; mild-to-moderate cases rarely do.
Seeing a rheumatologist or pain specialist who recognizes and documents fibromyalgia is essential. The physician completing Part B of the T2201 must be knowledgeable about your condition and willing to describe functional limitations specifically. A skeptical doctor will complete the form in a way that almost certainly results in denial.
Yes, cognitive impairment from fibromyalgia can contribute to a DTC claim under the mental functions category. "Fibro fog" affecting memory, concentration, problem-solving, and adaptive functioning can be documented and assessed by CRA as part of the mental functions criterion.